Polycystic Kidney Disease Therapeutics - Pipeline Analysis,2017

1
Surge in the Number of Pre-Clinical and Discovery
stage Drug Candidates Indicated in Polycystic
Kidney Disease (PKD) Therapeutics Pipeline
2
Polycystic Kidney Disease (PKD) Therapeutics
Polycystic Kidney Disease Pipeline in 2017
The study analyzed that the polycystic kidney
disease (PKD) therapeutics pipeline comprises
approximately 16 drug candidates in different
stages of development. PKD affects kidney along
with other organs, in which development of cyst
interrupts the ability to filter the waste
products from blood. The disease is mostly
related to high blood pressure, blood in urine,
pain in back, kidney stones and heart valve
abnormalities. Enlargement of cyst may lead to
kidney failure which can in turn impact other
organs. People with PKD are at a risk of
developing aneurysm in aorta or in blood vessels
in base of the brain. The disease can be
categorized into two types, as autosomal dominant
polycystic kidney disease (AKPKD), and autosomal
recessive polycystic kidney disease (ARPKD).
AKPKD generally diagnosed in adulthood, while
ARPKD diagnosed in earliest months of life.
3
Polycystic Kidney Disease (PKD) Therapeutics
Insights on pipeline segments
According to the research findings, most of the
drug candidates of the PKD are being developed to
be administered by the oral route.
Surge in the development of Pre-Clinical and
Discovery Drug Candidates
Many pharmaceutical companies are involved in the
development of therapeutic compounds by
overcoming the challenges, that are effective in
the treatment of PKD. They are focusing on
developing the maximum drug candidates in the
Pre-Clinical and Discovery stage of development.
The pipeline consists of approximately eight drug
candidates in the Pre-Clinical stage. GLG Pharma
is in the process of developing two drug
candidates in Pre-Clinical stage. Access Report
Summary with Detailed TOC on Polycystic Kidney
Disease (PKD) Therapeutics Pipeline Analysis,
2017 - Clinical Trials Results, Patents,
Designations, Collaborations, and Other
Developments at https//www.psmarketresearch.com
/market-analysis/polycystic-kidney-disease-therape
utics-pipeline-analysis
4
Polycystic Kidney Disease (PKD) Therapeutics
Increased Funding by the Government Organizations
Contributing Immensely in Pipeline Growth
Novatarg Pharmaceuticals, received 3.2 million
funding by Small Business Innovation Research
(SBIR), a part of governmental agencies of
National Institutes of Health, to further conduct
clinical study in PKD. Novatarg Pharmaceuticals,
is in the process of research and development
activities of NT 1044. Through the funding,
NovaTarg Pharmaceuticals had further planned to
progress drug candidates for PKD and type II
diabetes mellitus. In addition, the National
Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) is also supporting the
pharmaceutical companies to conduct clinical
study and research on PKD to improve patient
health. Some of the key players developing drugs
for the treatment of PKD therapeutics include
Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc.,
and XORTX Pharma Corp.
5
Polycystic Kidney Disease (PKD) Therapeutics
Download report sample at
https//www.psmarketresearch.com/market-analysis/p
olycystic-kidney-disease-therapeutics-pipeline-ana
lysis/report-sample
6
GET IN TOUCH
THANK YOU!
For information regarding permissions and other
queries Kindly write to
US/Canada Toll-Free 1-888-778-7886